title: The metabolism of salicylazosulphapyridine in ulcerative colitis. I. The relationship between metabolites and the response to treatment in inpatients.
abstract: The metabolism of salicylazosulphapyridine was studied in 16 patients with ulcerative colitis admitted to hospital. The acetylator phenotype was determined on admission. The mean serum concentration (mug/ml) (at steady state eight +/- two days in patients responding to treatment) of SASP, total SP, and 5-ASA were 18.7 +/- 12.8; 53.7 +/- 23.1; and 1 +/- 0.9 for slow acetylators and 17.6 +/- 7.1; 31 +/- 9.0 and 1 +/- 0.9 for fast acetylators respectively. Twenty-four hour urinary excretion of SASP, total SP, and 5-ASA were 4.6% +/- 3.1; 52% +/- 9.6 and 22.3 +/- 6.7% of the administered dose respectively. Serum total SP concentration of 20 to 50 mug/ml appeared to coincide with clinical improvement in the absence of any side effects related to salicylazosulphapyridine. No such relationship could be shown with serum SASP, individual metabolites, or 5-aminosalicyclic acid.
mesh_terms: D000107:Acetylation; D000324:Adrenocorticotropic Hormone / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000636:Aminosalicylic Acids / Q000378:metabolism; D003093:Colitis, Ulcerative / Q000378:metabolism*; D006801:Humans; D007273:Injections, Intramuscular; D008875:Middle Aged; D010641:Phenotype; D011239:Prednisolone / Q000627:therapeutic use; D012812:Sigmoidoscopy; D012460:Sulfasalazine / Q000097:blood / Q000378:metabolism*; D013607:Tablets; D013608:Tablets, Enteric-Coated
chemical_list: D000636:Aminosalicylic Acids; D013607:Tablets; D013608:Tablets, Enteric-Coated; D012460:Sulfasalazine; D000324:Adrenocorticotropic Hormone; D011239:Prednisolone